Tenofovir alafenamide
chemical compound
Tenofovir alafenamide (TAF), sold under the brand name Vemlidy, is an antiviral medication used against hepatitis B and HIV. It is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease and is given in combination with other medications for the prevention and treatment of HIV. It is taken by mouth.
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor and is a prodrug of tenofovir. It was developed by Gilead Sciences based on the protide technology of Chris McGuigan and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. It was approved for use in the US for HIV in 2015, and for hepatitis B in 2016. Although the US Food and Drug Administration (FDA) has approved tenofovir alafenamide for manufacture as a generic medication, it is not available.
A generic combination of Emtricitabine/tenofovir alafenamide (Viatris) received marketing authorization in the European Union in July 2025.
Fixed-dose combinations containing tenofovir alafenamide
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) — approved both in the United States and in the European Union in November 2015, (compare elvitegravir/cobicistat/emtricitabine/tenofovir; (Stribild))
Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) — approved in the United States in March 2016, and in the European Union in June 2016, (compare Emtricitabine/rilpivirine/tenofovir; (Complera))
Emtricitabine/tenofovir alafenamide (Descovy) — approved in the European Union and the United States in April 2016 (compare emtricitabine/tenofovir; (Truvada)). In October 2019, Descovy was approved in the United States for HIV-1 pre-exposure prophylaxis (PrEP).
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) — approved in the United States in February 2018.
The public source identifies “Tenofovir alafenamide” as chemical compound. This brief keeps that definition visible, then builds a research path around Tenofovir, alafenamide and chemical.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Tenofovir alafenamide”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated May 31, 2026. The linked authority identifier is Q22075912. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2015, 2016, 2025 and 2019.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Tenofovir alafenamide”, its source revision and the description used here.
- Expand the search: follow Tenofovir alafenamide primary sources, Tenofovir alafenamide archive and Tenofovir research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Tenofovir alafenamide”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Tenofovir alafenamide” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.